Recent Company News

• 04:02 AM ET Oct 23, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:23 AM ET Nov 05, 2026
  

  Vicore Pharma Holding reports Q3 EPS (SEK0.44) vs FactSet (SEK0.51) [4 est, (SEK0.55)-(0.48)] (SEK 9.20, 0.00)

• 02:20 AM ET Nov 05, 2026
  

  Vicore Pharma Announces Third Quarter 2026 Financial Results and Provides Business Update

• 01:34 AM ET Nov 05, 2026
  

  Vicore Pharma Holding initiated buy at Arctic Securities (SEK 9.20, 0.00)

• 10:31 PM ET Nov 04, 2026
  

  Vicore Pharma Holding initiated buy at Chardan Capital ($9.44, 0.00)

• 02:20 AM ET Nov 03, 2026
  

  Vicore Announces the Nomination Committee for the 2027 Annual General Meeting

• 02:32 AM ET Oct 23, 2026
  

  Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results

• 12:53 PM ET Oct 22, 2026
  

  Vicore's Phase 2B ASPIRE Trial of Buloxibutid in IPF passes pre-Planned futility analysis; Remains on track for Mid-2027 Topline results (SEK 8.88, 0.00)

• 02:33 PM ET Oct 20, 2026
  

  Transcript Intelligence: Vicore Pharma Holding at Chardan Healthcare Conference